Avram Hershko, Aaron Ciechanover, and Irwin Rose discovered how cells mark selected proteins with ubiquitin and direct them to the proteasome for breakdown. Their 2004 Nobel Prize recognized this basic mechanism of cellular regulation; later research on the proteasome produced treatments such as bortezomib.
How the ubiquitin tag directs breakdown
Ubiquitin is a small protein made of 76 amino acids. Enzymes attach ubiquitin molecules to a target protein; this tag signals the proteasome, a large protein complex that degrades the target. The system lets cells regulate the amount and timing of proteins involved in processes such as the cell cycle and DNA repair. The Nobel citation names the discovery as ubiquitin-mediated protein degradation.
Hershko and Ciechanover carried out key research at the Technion in Haifa, working with Rose, who was at Fox Chase Cancer Center in Philadelphia. The Nobel record documents the prize and the researchers’ institutions. Ciechanover’s Nobel profile describes this research history.
From cell biology to treatment
The discovery gave later researchers a defined pathway to investigate. Bortezomib inhibits proteasome activity and is approved to treat multiple myeloma and mantle cell lymphoma in specified patients. This is a later therapeutic application of proteasome research, not the treatment discovered by the Nobel laureates. The National Cancer Institute’s drug record lists its approved cancer uses.
For the full prize roster, see Israeli and Israel-linked Nobel laureates in science.